LISCure Biosciences
LISCure Biosciences is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the therapeutic areas where high unmet medical needs exist. LISCure Biosciences creates the "Next Generation Microbial Therapeutics" utilizing our own screening platform technology based on a proprietary in-house microorganism bank. Our phase 2 drug candidate has been designated as an orphan drug by the US FDA in 2022.
Location: Korea